

## **RTOG AdEERS Studies**

- 8531 Phase III Study of Zoladex Adjuvant to Radiotherapy in Unfavorable Prognosis Carcinoma of the Prostate**
- 9202 Phase III Trial of the Use of Long Term Total Androgen Suppression in Unfavorable Prognosis Carcinoma of the Prostate**
- 9513 Phase II Study of Topotecan Plus Cranial Radiation for Glioblastoma Multiforme**
- 9806 Phase II Study of Conventional Radiation Therapy Followed by Thalidomide for Supratentorial Glioblastoma**
- 0020 A Randomized Phase II Trial of Weekly Gemcitabine, Paclitaxel and External Irradiation (50.4 GY) Followed by the Farnesyl Transferase Inhibitor R115777 (NSC #702818) for Locally Advanced Pancreatic Cancer**
- 0118 Phase III Study of Conventional Radiation Therapy Plus Thalidomide (NSC# 66847) Versus Conventional Radiation Therapy for Multiple Brain Metastases**
- 0132 Phase II Trial of Neoadjuvant/Adjuvant STI-571 (GLEEVEC NSC #716051) for Primary and Recurrent Operable Malignant Gist Expressing the Kit Receptor Tyrosine Kinase (CD117) (ACRIN 6665)**
- 0211 A Phase I/II Study of an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), ZD 1839 (IRESSA), [NSC# 715055] with Radiation Therapy in Glioblastoma Multiforme**
- 0234 A Phase II Randomized Trial of Surgery Followed by Chemoradiotherapy Plus C225 (CETUXIMAB) for Advanced Squamous Cell Carcinoma of the Head and Neck**
- 0324 A Phase II Study of Cetuximab (C225) in Combination with Chemoradiation in Patients with Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)**